HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
26 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
EEF2
eukaryotic translation elongation factor 2
Chromosome 19 Β· 19p13.3
NCBI Gene: 1938Ensembl: ENSG00000167658.17HGNC: HGNC:3214UniProt: P13639
402PubMed Papers
21Diseases
9Drugs
7Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
RESEARCH IMPACT
Highly StudiedTrending
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
ribonucleoprotein complextranslational elongationribosome bindingcadherin bindingspinocerebellar ataxia type 26neoplasmCutaneous T-cell lymphomahairy cell leukemia
✦AI Summary

EEF2 (eukaryotic translation elongation factor 2) is a critical component of protein synthesis that catalyzes the GTP-dependent ribosomal translocation step during translation elongation, facilitating the coordinated movement of tRNA molecules and mRNA through the ribosome 1. The protein's activity is primarily regulated through phosphorylation at Thr56 by eEF2 kinase (eEF2K), which inactivates EEF2 and inhibits translational elongation 2. EEF2 function is modulated by several regulatory proteins, including PQBP1, which binds to non-phosphorylated EEF2 and suppresses eEF2K-mediated phosphorylation, thereby promoting protein synthesis 2. The protein also interacts with LDHA in a NADH-dependent manner, controlling EEF2's participation in ribosomal translation 3. EEF2 plays important roles in neuroplasticity, particularly in ketamine's antidepressant effects through BDNF translation regulation 4, and in hippocampal mGluR-dependent long-term depression 2. Additionally, EEF2 facilitates translation of specific mRNAs through binding to modified sites, such as ac4C-modified HMGB2 mRNA in hepatocellular carcinoma 5. Pathologically, EEF2 is targeted by bacterial toxins like exotoxin A, leading to ribotoxic stress and inflammasome activation 6, and is associated with muscle atrophy through interaction with circDdb1-867aa protein 7.

Sources cited
1
EEF2 catalyzes GTP-dependent ribosomal translocation during translation elongation
PMID: 26593721
2
EEF2 is phosphorylated at Thr56 by eEF2K which inactivates it, and PQBP1 suppresses this phosphorylation
PMID: 33662272
3
LDHA interacts with EEF2 in a NADH-dependent manner to control translation participation
PMID: 35176139
4
EEF2 is involved in ketamine's antidepressant effects through BDNF translation regulation
PMID: 26519901
5
EEF2 binds to ac4C-modified HMGB2 mRNA sites to enhance translation
PMID: 39030964
6
EEF2 is targeted by bacterial exotoxin A causing ribotoxic stress and inflammasome activation
PMID: 37642996
7
EEF2 interacts with circDdb1-867aa protein in muscle atrophy regulation
PMID: 39412095
Disease Associationsβ“˜21
spinocerebellar ataxia type 26Open Targets
0.60Moderate
neoplasmOpen Targets
0.54Moderate
Cutaneous T-cell lymphomaOpen Targets
0.51Moderate
hairy cell leukemiaOpen Targets
0.50Moderate
neurodegenerative diseaseOpen Targets
0.49Moderate
HydrocephalusOpen Targets
0.46Moderate
lymphomaOpen Targets
0.46Moderate
Parkinson diseaseOpen Targets
0.42Moderate
Alzheimer diseaseOpen Targets
0.42Moderate
lysosomal storage diseaseOpen Targets
0.41Moderate
multiple sclerosisOpen Targets
0.41Moderate
acute myeloid leukemiaOpen Targets
0.41Moderate
blastic plasmacytoid dendritic cell neoplasmOpen Targets
0.39Weak
acute myeloid leukemia by FAB classificationOpen Targets
0.39Weak
neuroinflammatory disorderOpen Targets
0.38Weak
Neurodevelopmental disorderOpen Targets
0.37Weak
diphtheriaOpen Targets
0.37Weak
childhood leukemiaOpen Targets
0.37Weak
MacrocephalyOpen Targets
0.37Weak
mature T-cell and NK-cell non-Hodgkin lymphomaOpen Targets
0.37Weak
Spinocerebellar ataxia 26UniProt
Pathogenic Variants7
NM_001961.4(EEF2):c.1592A>C (p.Asp531Ala)Likely pathogenic
not specified
β˜…β˜†β˜†β˜†2025β†’ Residue 531
NM_001961.4(EEF2):c.2303G>A (p.Gly768Asp)Likely pathogenic
EEF2-related neurodevelopmental disorder with multiple anomalies
β˜…β˜†β˜†β˜†2024β†’ Residue 768
NM_001961.4(EEF2):c.328G>A (p.Asp110Asn)Pathogenic
not provided
β˜…β˜†β˜†β˜†2023β†’ Residue 110
NM_001961.4(EEF2):c.2008dup (p.Gln670fs)Likely pathogenic
EEF2-related neurodevelopmental disorder with multiple anomalies
β˜…β˜†β˜†β˜†2023β†’ Residue 670
NM_001961.4(EEF2):c.433C>T (p.Gln145Ter)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2022β†’ Residue 145
NM_001961.4(EEF2):c.1787C>A (p.Pro596His)Pathogenic
Spinocerebellar ataxia type 26|not provided
β˜…β˜†β˜†β˜†2019β†’ Residue 596
NM_001961.4(EEF2):c.2314G>A (p.Glu772Lys)Likely pathogenic
Spinocerebellar ataxia type 26
β˜†β˜†β˜†β˜†2022β†’ Residue 772
View on ClinVar β†—
Drug Targets9
CINTREDEKIN BESUDOTOXPhase III
Interleukin 13 receptor binding agent
brain cancer
DENILEUKIN DIFTITOXApproved
Interleukin-2 receptor binding agent
Cutaneous T-cell lymphoma
LMB-100Phase II
Mesothelin binding agent
mesothelioma
LMB-2Phase II
Interleukin-2 receptor alpha chain binding agent
chronic lymphocytic leukemia
LMB-7Phase I
Elongation factor 2 inhibitor
Central Nervous System Neoplasm
MOXETUMOMAB PASUDOTOXApproved
Elongation factor 2 inhibitor
OPORTUZUMAB MONATOXApproved
Elongation factor 2 inhibitor
neoplasm
RESIMMUNEPhase II
Elongation factor 2 inhibitor
Cutaneous T-cell lymphoma
TAGRAXOFUSPApproved
Elongation factor 2 inhibitor
Related Genes
RPL12Protein interaction100%RPS9Protein interaction100%RPS23Protein interaction100%RPL38Protein interaction100%RPL27Protein interaction100%RPLP0Protein interaction100%
Tissue Expression6 tissues
Ovary
100%
Heart
75%
Brain
72%
Lung
54%
Bone Marrow
47%
Liver
45%
Gene Interaction Network
Click a node to explore
EEF2RPL12RPS9RPS23RPL38RPL27RPLP0
PROTEIN STRUCTURE
Preparing viewer…
PDB8XSX Β· 2.40 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.39Moderately Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.27 [0.19–0.39]
RankingsWhere EEF2 stands among ~20K protein-coding genes
  • #722of 20,598
    Most Researched402 Β· top 5%
  • #367of 1,025
    FDA-Approved Drug Targets4
  • #3,148of 5,498
    Most Pathogenic Variants7
  • #1,903of 17,882
    Most Constrained (LOEUF)0.39 Β· top quartile
Genes detectedEEF2
Sources retrieved26 papers
Response timeβ€”
πŸ“„ Sources
26β–Ό
1
Mechanisms of ketamine action as an antidepressant.
PMID: 29532791
Mol Psychiatry Β· 2018
1.00
2
BDNF - a key transducer of antidepressant effects.
PMID: 26519901
Neuropharmacology Β· 2016
0.90
3
Inhibition of LDHA to induce eEF2 release enhances thrombocytopoiesis.
PMID: 35176139
Blood Β· 2022
0.80
4
FAM86A methylation of eEF2 links mRNA translation elongation to tumorigenesis.
PMID: 38508183
Mol Cell Β· 2024
0.72
5
Targeting N4-acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2-mediated HMGB2 mRNA translation.
PMID: 39030964
Cancer Commun (Lond) Β· 2024
0.70